Novavax

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novavax and other ETFs, options, and stocks.

About NVAX

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. 

CEO
Stanley C. Erck
CEOStanley C. Erck
Employees
1,541
Employees1,541
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1987
Founded1987
Employees
1,541
Employees1,541

NVAX Key Statistics

Market cap
1.33B
Market cap1.33B
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
4.65M
Average volume4.65M
High today
$16.96
High today$16.96
Low today
$15.53
Low today$15.53
Open price
$16.52
Open price$16.52
Volume
6.19M
Volume6.19M
52 Week high
$236.50
52 Week high$236.50
52 Week low
$15.53
52 Week low$15.53

NVAX News

MarketWatch 3d
Aptamer Group Wins Number of New Contracts - MarketWatch

By Joe Hoppe Aptamer Group PLC said Thursday that it has secured a number of new contract wins, with the potential for future downstream royalties and mileston...

Aptamer Group Wins Number of New Contracts - MarketWatch
Investor's Business Daily 5d
Is Novavax Stock A Buy On Its Massive Sales Beat Despite Unexpected Losses?

Novavax (NVAX) quadrupled its sales in the third quarter, though delivered an unexpected per-share loss — leading NVAX stock to pop after its earnings report....

Is Novavax Stock A Buy On Its Massive Sales Beat Despite Unexpected Losses?
Benzinga 5d
What's Going On With Novavax Stock?

Novavax Inc NVAX shares are trading higher Tuesday after the company announced the World Health Organization (WHO) issued an updated Emergency Use Listing for i...

What's Going On With Novavax Stock?

Analyst ratings

50%

of 6 ratings
Buy
50%
Hold
16.7%
Sell
33.3%

NVAX Earnings

-$11.18
-$5.33
$0.51
$6.36
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Feb 27, After Hours
ActualExpected Feb 27, After Hours

More NVAX News

MarketWatch 5d
Novavax Gets WHO Sign-Off on Covid Booster, Use For Kids - MarketWatch

By Will Feuer Novavax Inc. said the World Health Organization has issued an updated emergency use listing for its Covid-19 vaccine, Nuvaxovid, to expand its us...

Novavax Gets WHO Sign-Off on Covid Booster, Use For Kids - MarketWatch
Benzinga 5d
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Prima - Benzinga

GAITHERSBURG, Md., Nov. 29, 2022 /PRNewswire/ -- Novavax, Inc. NVAX, a biotechnology company dedicated to developing and commercializing next-generation vaccine...

World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Prima - Benzinga
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.